University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
School of Medicine Publications and
Presentations

School of Medicine

9-2021

Hemorrhagic stroke outcomes of KApSR patients with co-morbid
diabetes and Alzheimer’s disease
Amanda L. Trout
Christopher J. McLouth
Patrick Kitzman
Michael R. Dobbs
The University of Texas Rio Grande Valley

Lisa Bellamy

See next page for additional authors

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub
Part of the Medicine and Health Sciences Commons

Recommended Citation
Trout, A. L., McLouth, C. J., Kitzman, P., Dobbs, M. R., Bellamy, L., Elkins, K., & Fraser, J. F. (2021).
Hemorrhagic stroke outcomes of KApSR patients with co-morbid diabetes and Alzheimer’s disease.
Annals of Translational Medicine, 9(17), 1371–1371. https://doi.org/10.21037/atm-21-1451

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has
been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator
of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu,
william.flores01@utrgv.edu.

Authors
Amanda L. Trout, Christopher J. McLouth, Patrick Kitzman, Michael R. Dobbs, Lisa Bellamy, Kelley Elkins,
and Justin F. Fraser

This article is available at ScholarWorks @ UTRGV: https://scholarworks.utrgv.edu/som_pub/414

Original Article

Page 1 of 12

Hemorrhagic stroke outcomes of KApSR patients with co-morbid
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Background: Vascular risk factors, such as diabetes mellitus (DM), are associated with poorer outcomes
following many neurodegenerative diseases, including hemorrhagic stroke and Alzheimer’s disease (AD).
Combined AD and DM co-morbidities are associated with an increased risk of hemorrhagic stroke and
increased Medicare costs. Therefore, we hypothesized that patients with DM in combination with AD,
termed DM/AD, would have increased hemorrhagic stroke severity.
Methods: Kentucky Appalachian Stroke Registry (KApSR) is a database of demographic and clinical data
from patients that live in Appalachia, a distinct region with increased health disparities and stroke severity.
Inpatients with a primary indication of hemorrhagic stroke were selected from KApSR for retrospective
analysis and were separated into four groups: DM only, AD only, neither, or both.
Results: Hemorrhagic stroke patients (2,071 total) presented with either intracerebral hemorrhage (ICH),
n=1,448, or subarachnoid hemorrhage (SAH), n=623. When examining all four groups, subjects with AD
were significantly older (AD+, 80.9±6.6 yrs) (DM+/AD+, 77.4±10.0 yrs) than non AD subjects (DM-/AD-,
61.3±16.5 yrs) and (DM+, 66.0±12.5 yrs). A higher percentage of females were among the AD+ group
and a higher percentage of males among the DM+/AD+ group. Interestingly, after adjusting for multiple
comparison, DM+/AD+ subjects were ten times as likely to suffer a moderate to severe stroke based on a
National Institute of Health Stroke (NIHSS) upon admission [odds ratio (95% CI)] compared to DM-/
AD- [0.1 (0.02–0.55)], DM+ [0.11 (0.02–0.59)], and AD+ [0.09(0.01–0.63)]. The odds of DM+/AD+ subjects
having an unfavorable discharge destination (death, hospice, long-term care) was significant (P<0.05) from
DM-/AD- [0.26 (0.07–0.96)] when adjusting for sex, age, and comorbidities.
Conclusions: In our retrospective analysis utilizing KApSR, regardless of adjusting for age, sex, and
comorbidities, DM+/AD+ patients were significantly more likely to have had a moderate or severe stroke
leading to an unfavorable outcome following hemorrhagic stroke.
Keywords: Appalachia; Kentucky Appalachian Stroke Registry (KApSR); dementia
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Introduction
Kentucky and West Virginia lie within a portion of rural
Appalachia, a population with an increased burden of
negative health disparities (1-3). According to the United
Heath Foundation, as of 2019, Kentucky and West Virginia
ranked 43rd and 45th out of 50, respectively, for overall
health in the US. Contributing to this overall negative heath
disparity are their rankings of 44th and 46th for stroke and
44th and 50th for diabetes, respectively. Using Medicare
costs as a measure of overall health (i.e., high Medicare cost
indicates poor health), diabetes mellitus (DM; i.e., type 2
diabetes), has been shown to increase cost by a factor of
2.3 (4). DM is associated with an increased risk of
Alzheimer’s disease (AD) (5-7) and poorer outcomes
following stroke (8). AD is also an additive comorbidity
that doubles Medicare cost when associated with stroke
and diabetes (9) and has an increased risk of hemorrhagic
stroke (10). Stroke, AD, and DM are among the top 7
leading causes of death, not only in Kentucky and West
Virginia (11), but globally (12). Many retrospective studies
have examined how a single comorbidity influences a
neurological disease, such as hemorrhagic stroke, but few
have looked at the effect of dual comorbidities or specifically
how AD influences hemorrhagic stroke outcomes.
The Kentucky Appalachian Stroke Registry (KApSR) is
a database of demographic and clinical data from patients
in the rural Kentucky and West Virgina regions with
stroke (13). In this study, we used KApSR to retrospectively
analyze the contributions of diabetes and AD to outcomes
following hemorrhagic stroke such as length of stay,
discharge destination, change in National Institute of
Health Stroke (NIHSS), and 30-day readmission rates. Our
central aim was to examine the relationship between the
combination of diabetes and AD and hemorrhagic stroke
severity.
We present the following article in accordance with the
STROBE reporting checklist (available at https://dx.doi.
org/10.21037/atm-21-1451).
Methods
Ethical statement
The study was conducted in accordance with the
Declaration of Helsinki (as revised in 2013). The study
was approved by Kentucky Appalachian Stroke Registry
(KApSR) (de-identified data provided under IRB# 1308058) and individual consent for this retrospective analysis
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was waived.
Study sample
Kentucky Appalachian Stroke Registry (KApSR) is a
database of demographic and clinical data from patients
that live in Appalachia Kentucky (13), a distinct region with
increased health disparities and stroke severity. A crosssectional analysis of inpatients with cardiovascular disease
(CVD) containing a principle diagnosis of hemorrhagic
stroke were evaluated for DM and/or AD in the KApSR
database from 2010–2018. Hemorrhagic stroke patients
were identified in KApSR as presenting with intracerebral
hemorrhage (ICH) or subarachnoid hemorrhage (SAH),
methods previously described (13). Briefly, demographics,
comorbidities (defined by International Classification of
Disease (ICD) codes), glycated hemoglobin A1 (hbA1c)
values, previous diagnosis of AD, and outcome measures
were collected from electronic health records (EHR) for
inpatients, >18 years old, with an ICH or SAH, ICD9 codes:
431 and 430; ICD10 codes of 161 and 160, respectively. The
accuracy of using EHR in KApSR was previously validated
and reported by Kitzman et al. (13). We separated patients
into four comorbidity categories: no previous diagnosis of
DM or AD (DM-/AD-), DM only (DM+), AD only (AD+),
or combined DM and AD (DM+/AD+).
Outcomes
Admission and discharge NIHSS were collected, along
with length of stay, and discharge destination (favorable or
unfavorable). Favorable discharge destinations include: alive/
routine, transfer to other institution, hospital swing bed,
or home health services, rehabilitation facility/unit, against
medical advice, police case, or billin. Unfavorable discharge
destinations include: death (≤48 or >48 hrs), hospice, skilled
nursing facility, or long-term care hospital. Change in
NIHSS from admission to discharge was measured as an
indicator of short-term inpatient outcome (14).
Statistical analysis
Demographic characteristics are presented without
adjustment for covariates as mean ± standard deviation
or sample number (percentages). A1Cs were categorized
as normal (<5.7%) or as abnormal (≥5.7%) (15,16) that
included diabetics (A1C ≥6.5%) and prediabetics (5.7≤
A1C <6.5) (17). Between-group differences in demographic
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characteristics were investigated using a series of oneway ANOVAs for continuous variables and Chi-square or
Fisher’s exact tests for categorical variables. Differences
in non-normal continuous variables were assessed using a
Kruskal-Wallis test. Significant between group differences
were used as control variables in model 3 of the main
outcome analysis (described below). To investigate between
group differences in the main outcome variables, three
models were employed. Model 1 was unadjusted, model
2 was adjusted for age and sex, and model 3 was adjusted
for age, sex, type of hemorrhage, race, and all significant
comorbidities (other than DM and AD). The DM/AD was
the reference group for all analyses. Depending on the
distribution of the outcome, these models were analyzed
using linear regression, logistic regression, or ordinal
logistic regression. Due to its non-normal distribution and
inability to achieve normality under any data transformation,
NIHSS was recoded into an ordinal variable defined as: 0–5=
mild, 6–13= moderate, and >13= severe stroke (18-20). The
change (Admission-Discharge) in NIHSS was transformed
into an ordinal variable based on whether the patient was:
declining, staying the same, or improving. This change
was based on the continuous NIHSS value. Discharge
destination, a binary variable, was classified as favorable or
unfavorable using the rules outlined above. Length of stay
positively skewed and was log transformed to approximate
normality. For all models, odds ratios and 95% confidence
intervals (CI) were calculated for all outcome measures.
For each outcome, Dunnett’s procedure was used to correct
for multiple comparisons, since each category was being
compared against the DM/AD condition (21). Graphical
and statistical analysis was performed using Graphpad
Prism and SAS version 9.4 (SAS Institute Inc.).
Missing data and statistical assumption
NIHSS, the main outcome, was missing for 40.2% (n=833)
of the sample. Our hospital institution transitioned from
the Primary Stroke Center to a Comprehensive Stroke
Center in 2013, and our standards and mechanisms for
documentation in the EMR changed. These evolutions
could account for missing data points in our study, which,
unfortunately, could not be recovered. A missing data
analysis was performed using demographic and comorbidity
variables as predictors of missingness in a multivariable
logistic regression. Table S1 (see supplemental materials)
contains the results of this analysis. The following
characteristics and comorbidities were associated with
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lower odds of having missing NIHSS: older age, current
hypertension, tobacco use, dyslipidemia and carotid
stenosis. Females and those with SAH stroke type had
higher levels of missing data. There were no significant
differences between AD or DM conditions. These variables
were included in the models where NIHSS were the
outcome of interest. No covariates contained missing data.
As a result of missing NIHSS data and a small sample
for the main comparison condition (DM+/AD+), a there is
a concern for the violation of statistical assumptions due to
the small expected cell sizes for the contingency tables of
Model 1 (described above). To address this concern, Fisher’s
exact tests, a nonparametric version of a chi-square test of
independence, was performed on NIHSS outcomes for all
pairwise comparisons where DM+/AD+ was the reference
group. The substantive results of these tests aligned with
the parametric versions reported in the results. Despite
certain statistical assumptions of our model not being met,
the agreement between these two sets of analyses lends
credence to our interpretations.
Results
Demographic characteristics
A total of 2,071 patients with hemorrhagic stroke were
included: 1,459 (70.4%) were without DM and AD (DM-/
AD-), 567 (27.4%) had DM alone (DM+), 29 (1.4%) had
AD alone (AD+), and 16 had both DM and AD (DM+/
AD+). Table 1 presents descriptive statistics for the
demographic and comorbidity variables with between group
comparisons. There were significant (P<0.0001) differences
in the age of the groups (Figure 1A): 61.3±16.5 yrs (DM-/
AD-) to 66.01±12.5 yrs (DM+), 80.9±6.6 yrs (AD+), and
77.4±10.0 yrs (DM+/AD+). Patients with an AD diagnosis
(AD+ or DM+/AD+) were significantly (P<0.0001, P<0.05,
respectively) older than DM alone. Sex was significantly
(P<0.05) different among the groups, with ~50% female
for DM-/AD- and DM+ to ~76% female in AD+ and
~31% female in DM+/ AD+ (Figure 1B). A significantly
higher percentage of DM+ (P<0.0001) and AD+ (P<0.01),
compared to the DM-/AD- (Figure 1C), had a prior
stroke. DM+/AD+ followed this trend but did not reach
significance (P=0.08). No statistical difference among race
in the four groups was observed (Table 1). Across the four
groups, ICH was more common than SAH (Figure 1D),
with DM+ and AD+ having significantly more ICH than
SAH compared to DM-/AD-.
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Table 1 Demographics of hemorrhagic stroke patients in KApSR
Variable

-DM/-AD

DM

AD

DM/AD

Total N

1,459 (70.4%)

567 (27.4%)

29 (1.4%)

16 (0.8%)

61.3±16.5

66.0±12.5

80.9±6.6

Sex, female, N (%)

745 (51.1%)

290 (51.1%)

Stroke type, ICH, n (%)

974 (66.8%)

436 (76.9%)

Age, yrs (mean ± SD)

Test statistic

P value

77.4±10.0

31.1

<0.0001

22 (75.9%)

5 (31.3%)

9.615

0.0221

25 (86.2%)

13 (81.3%)

24.69

<0.0001

Race, n (%)

0.2954

White

1,317 (90.3%)

565 (99.8%)

29 (100%)

12 (75%)

Black

107 (7.3%)

0

0

4 (25%)

Asian

11 (0.8%)

0

0

0

Hispanic

3 (0.2%)

0

0

0

Other/non-Hispanic

8 (0.5%)

1 (0.2%)

0

0

Refused/unreported

13 (0.9%)

1 (0.2%)

0

0

225 (15.4%)

130 (22.9%)

10 (34.5%)

5 (31.3%)

23.25

<0.0001

208 (14%)

131 (23%)

9 (31.0%)

6 (38.0%)

31.42

<0.0001

Coronary artery disease

258 (17.7%)

205 (36.2%)

11 (37.9%))

9 (56.3%)

91.32

<0.0001

Dyslipidemia

470 (32.2%)

324 (57.1%)

14 (48.3%)

10 (62.5%)

110.7

<0.0001

Hypertension

1,233 (84.6%)

544 (95.9%)

22 (75.9%)

14 (87.5%)

52.63

<0.0001

177 (12.1%)

127 (22.4%)

2 (6.9%)

1 (6.25%)

36.52

<0.0001

Carotid stenosis

42 (2.9%)

36 (6.3%)

1 (3.4%)

0

14.06

0.0048

History of myocardial infarction

72 (4.9%)

45 (7.9%)

1 (3.4%)

2 (12.5%)

8.351

0.0301

Acute myocardial infarction

78 (5.3%)

41 (7.2%)

0 (0)

2 (12.5%)

5.729

0.1036

600 (41.2%)

188 (33.2%)

6 (20.7%)

6 (37.5%)

15.14

0.0014

413

369

12

11

5.6±0.7

7.5±1.9

5.4±0.4

6.6±0.6

119.2

<0.0001

162 (39.0%)

326 (88%)

6 (50%)

10 (100)

207.8

<0.0001

7 [1–19]

7 [2–18]

9 [2–23]

19 [15–26]

Mild: 0–5

389 (46.6%)

160 (43.4%)

9 (39.1%)

1 (9.1%)

Moderate: 6–13

166 (19.9%)

78 (21.1%)

6 (26.1%)

1 (9.1%)

Severe: >13

280 (33.5%)

131 (35.5%)

8 (34.8%)

9 (81.8%)

6 [1–18]

6 [1–19]

12 [4–23]

19 [10–22]

Comorbidities, n (%)
Prior stroke/transient ischemic attack
Atrial fibrillation

Obesity

Tobacco
hbAIc
n
Mean ± SD
≥5.7 AIC (%)
†

Outcomes

Admission NIHSS value, median [IQR]
Ordinal admission NIHSS, n (%)

Discharge NIHSS value, median [IQR]
Table 1 (continued)
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Table 1 (continued)
Variable

-DM/-AD

DM

AD

DM/AD

Mild: 0–5

412 (49.3%)

179 (48.5%)

7 (30.4%)

0 (0%)

Moderate: 6–13

149 (17.8%)

68 (18.4%)

5 (21.7%)

4 (36.4%)

Severe: >13

274 (32.8%)

122 (33.1%)

11 (47.8%)

7 (63.6%)

0 [−1 to 1]

0 [−1 to 2]

0 [−4 to 1]

1 [0 to 7]

Decline

228 (27.3%)

108 (29.3%)

9 (39.1%)

2 (18.2%)

Stable

332 (39.8%)

122 (33.1%)

7 (30.4%)

3 (27.3%)

Improve

275 (32.9%)

139 (37.7%)

7 (30.4%)

6 (54.6%)

571 (39.1%)

240 (42.3%)

18 (62.1%)

12 (75.0%)

1.71 (1.09)

1.28 (0.90)

1.83 (1.10)

Test statistic

P value

Ordinal discharge NIHSS, n (%)

NIHSS change value, median [IQR]
Ordinal NIHSS change, n (%)

Unfavorable discharge, n (%)
Length of stay (log), mean (SD)

1.63 (1.16)

†

Data are mean ± SD and number with percent of population. , statistical analysis for outcome presented in Model 1 of Table 2. AD,
Alzheimer’s disease; DM, diabetes mellitus; F, female; hbA1c, glycosylated hemoglobin A1c; ICH, intracerebral hemorrhage; IQR,
interquartile range; KApSR, Kentucky Appalachian Stroke Registry; M, male; NIHSS, National Institutes of Health Stroke Scale; SD,
standard deviation; SAH, subarachnoid hemorrhage.

A

B

C

D

Figure 1 Hemorrhagic stroke demographic among KApSR. The average (A) age as well as percentage of (B) males to females, (C) patients
with a prior stroke, and (D) type of hemorrhagic stroke among the four subgroups (-DM/-AD, DM, AD, and DM/AD). Data are mean ±
SEM. P values were assessed by ANOVA or Chi-squared followed by followed by a Tukey’s post-hoc test or a 2×2 Chi-squared. *, P<0.05; **,
P<0.01; ***, P<0.001; ****, P<0.0001 indicates significance from -DM/-AD. ^, P<0.05; ^^, P<0.01; and ^^^^, P<0.0001 indicates significance
from DM. #P<0.05 indicates significance from AD. AD, Alzheimer’s disease; ANOVA, Analysis of Variance; DM, diabetes mellitus; ICH,
intracerebral hemorrhage; KApSR, Kentucky Appalachian Stroke Registry; TIA, transient ischemic attack; SEM, standard error of mean;
SAH, subarachnoid hemorrhage; yrs, years.
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A

B

C

D

E

F

G

Figure 2 Comorbidities among KApSR patients with hemorrhagic stroke. The percentage of patients with (A) atrial fibrillation, (B)
coronary artery disease, (C) dyslipidemia, (D) hypertension, (E) obesity, (F) hbA1c ≥5.6, and (G) tobacco use among the four subgroups
(–DM/-AD, +DM, +AD, and DM/AD). Data are represented as percentage of yes/no. P values were assessed by Chi-squared, 4×2, followed
by followed 2×2. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 indicates significance from -DM/-AD. ^P<0.05 and ^^^^P<0.0001 indicates
significance from DM. ##P<0.01 indicates significance from AD. AD, Alzheimer’s disease; DM, diabetes mellitus; hbA1c, glycosylated
hemoglobin A1c.

When evaluating comorbidities, a significantly higher
percentage of patients with atrial fibrillation (P<0.0001,
Figure 2A) and coronary artery disease (P<0.0001, Figure 2B)
were seen in DM+, AD+, and DM+/AD+ compared to
DM-/AD-. Dyslipidemia was only significantly (P<0.0001)
different among the subjects with DM (DM+ and DM+/
AD+, Figure 2C) compared to DM-/AD-. Hypertension
(P<0.0001, Figure 2D) and obesity (P<0.0001, Figure 2E)
increased in subjects with only DM, compared to DM-/ADand the AD groups. Differences in carotid stenosis (P<0.01)
and a history of, but not acute, myocardial infarction
(P<0.05) were observed with only the DM group compared
to the DM-/AD- group (Table 1). A significantly (P<0.0001,
Figure 2F) higher percentage of patients with A1C ≥5.6%
were among subjects with DM (DM+ and DM+/AD+)
compared to both DM-/AD- and AD. The percentage of
prediabetics/diabetics, based on abnormal A1Cs, increase

© Annals of Translational Medicine. All rights reserved.

from 39% (DM-/AD-) to 88% (DM+), 50% (AD+), and
100% (DM+/AD+; Figure 2F). Tobacco use (P<0.01,
Figure 2G) was significantly higher among DM and AD
groups compared to DM-/AD-.
Outcomes
Differences in NIHSS was assessed using ordinal logistic
regression. Results are presented in the first three sections
of Table 2. Regardless of adjusting for age, sex, and
comorbidities, DM+/AD+ patients were significantly more
likely to have had a moderate or severe stroke compared
to the other three groups. Using parameter estimates
from Model 3 (Table 2), DM+/AD+ patients were 10 times
(i.e., 1/0.10=10) more likely to have had a moderate or
severe stroke based on the admission NIHSS (Figure 3A).
At discharge, DM+/AD+ patients were approximately

Ann Transl Med 2021;9(17):1371 | https://dx.doi.org/10.21037/atm-21-1451
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Table 2 Regression analysis for outcome measures of hemorrhagic stroke patients
Model 1
Variable

Model 2

Model 3

Odds ratio
(SE)

95% CI

P value

Odds ratio
(SE)

95% CI

P value

Odds ratio
(SE)

95% CI

P value

-DM/-AD (n=835)

0.11 (0.78)

0.02–0.59

0.008

0.12 (0.78)

0.02–0.66

0.012

0.10 (0.80)

0.02–0.55

0.006

DM+ (n=369)

0.12 (0.78)

0.02–0.67

0.013

0.13 (0.78)

0.02–0.72

0.017

0.11 (0.80)

0.02–0.59

0.009

AD+ (n=23)

0.13 (0.87)

0.02–0.87

0.033

0.12 (0.87)

0.02–0.80

0.026

0.09 (0.88)

0.01–0.63

0.013

Admission NIHSS†

DM/AD (n=11)

1.0 (ref)

1.0 (ref)

1.0 (ref)

†

Discharge NIHSS

-DM/-AD (n=835)

0.21 (0.65)

0.05–0.86

0.028

0.25 (0.65)

0.06–1.03

0.055

0.22 (0.65)

0.05–0.92

0.036

DM+ (n=369)

0.21 (0.65)

0.05–0.89

0.032

0.24 (0.65)

0.06–1.00

0.050

0.22 (0.66)

0.05–0.91

0.036

AD+ (n=23)

0.42 (0.76)

0.08–2.18

0.366

0.38 (0.76)

0.07–1.97

0.297

0.32 (0.76)

0.06–1.70

0.211

DM/AD (n=11)

1.0 (ref)

1.0 (ref)

1.0 (ref)

Change NIHSS†
-DM/-AD (n=835)

0.46 (0.58)

0.13–1.62

0.270

0.41 (0.58)

0.11–1.46

0.195

0.37 (0.59)

0.10–1.35

0.151

DM+ (n=369)

0.49 (0.59)

0.14–1.77

0.335

0.46 (0.59)

0.13–1.66

0.282

0.44 (0.59)

0.12–1.57

0.243

AD+ (n=23)

0.32 (0.69)

0.07–1.47

0.166

0.36 (0.70)

0.08–1.64

0.219

0.34 (0.70)

0.07–1.55

0.187

DM/AD (n=11)

1.0 (ref)

1.0 (ref)

1.0 (ref)

‡

Unfavorable discharge
-DM/-AD (n=1,459)

0.21 (0.58)

0.06–0.76

0.014

0.33 (0.59)

0.09–1.19

0.097

0.26 (0.59)

0.07–0.96

0.040

DM+ (n=567)

0.25 (0.58)

0.07–0.87

0.028

0.33 (0.59)

0.09–1.20

0.099

0.31 (0.59)

0.08–1.29

0.078

AD+ (n=29)

0.55 (0.69)

0.12–2.46

0.532

0.46 (0.70)

0.10–2.10

0.383

0.36 (0.71)

0.08–1.70

0.234

DM/AD (n=16)

1.0 (ref)

1.0 (ref)

1.0 (ref)

Average stay (log
transformed)§

Mean (SE)

Mean (SE)

Mean (SE)

-DM/-AD (n=1,459)

1.63 (0.03)

0.489

1.61 (0.03)

0.177

1.95 (0.06)

0.748

DM+ (n=567)

1.71 (0.05)

0.684

1.74 (0.05)

0.381

1.92 (0.07)

0.657

AD+ (n=29)

1.28 (0.21)

0.123

1.47 (0.21)

0.138

1.82 (0.21)

0.515

DM/AD (n=16)

1.83 (0.28)

REF

1.99 (0.28)

REF

2.04 (0.27)

REF

DM+, AD+ served as the reference group for analysis. Data are odds ratios and 95% CI or mean (SE). Both P values and confidence
intervals were calculated using Dunnett’s multiple comparison procedure. Model 1: unadjusted; Model 2: adjusted for age and sex; Model
3: adjusted for age, sex, type of hemorrhage, race, and all comorbidities (other than DM and AD). NIHSS was transformed into ordinal
variables defined as: 0–5= mild, 6–13= moderate, and >13= severe stroke. The change (Admission-Discharge) in NIHSS was transformed
into an ordinal variable based on whether the patient was: declining, staying the same, or improving. Discharge destination transformed
into binary variable and classified as favorable or unfavorable. †Ordinal logistic regression. ‡Logistic regression. §Linear Regression. CI,
confidence interval; DM, diabetes mellitus; AD, Alzheimer’s disease; NIHSS, National Institutes of Health Stroke Scale; SE, standard error.
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A

B

C

D

Figure 3 Hemorrhagic stroke outcomes among KApSR patients. NIHSS was transformed into ordinal variables defined as: 0–5= mild, 6–13=
moderate, and >13= severe stroke for (A) admission and (B) discharge outcomes. (C) Inpatient outcomes defined as improving, same, or
declining NIHSS (Admission-Discharge). (D) Discharge destination transformed into binary variable classified as favorable or unfavorable.
Data are represented as percentage variables. P values were assessed by Chi-squared, 4×3, followed by followed 2×3. *P<0.05, **P<0.01 indicates
significance from -DM/-AD. ^P<0.05 and ^^P<0.01 indicates significance from DM. #P<0.05 indicates significance from AD. AD, Alzheimer’s
disease; DM, diabetes mellitus; KApSR, Kentucky Appalachian Stroke Registry; NIHSS, National Institute of Heath Stroke Scale.

4.5 times more likely to be in the moderate or severe
NIHSS categories compared to DM-/AD- and DM+,
which translated into DM+/AD+ subjects having a higher
percentage of strokes classified as severe at discharge
(Figure 3B). However, even though DM+/AD+ patients
had significantly worse admission and discharge NIHSS,
their change in NIHSS (admission–discharge) indicating
in patient outcome was not significantly different from the
other three groups (Figure 3C, Table 2).
The relationship between comorbidity condition and
experiencing an unfavorable discharge was examined
using logistic regression. The DM+/AD+ subjects had a
significantly higher percentage of unfavorable discharge
destinations compared to DM-/AD- and DM+ (Figure 3D).
Interestingly, when adjusting for age and sex (model 2),
discharge destination was not significantly different among
groups. However, in the unadjusted (model 1) and adjusted
for age, sex, and comorbidities (model 3; Table 2), the odds
of DM+/AD+ having an unfavorable discharge destination
was significant (P<0.05) from DM-/AD- and DM+. The
average number of days in the hospital (Table 2, regardless
of modeling) was not significantly different from the DM+/
AD+ group.
Several of the covariates included in Model 3 were

© Annals of Translational Medicine. All rights reserved.

significantly related to the outcomes. In particular, older
individuals were more likely to have had a moderate to
severe stroke based on their discharge NIHSS, they were
less likely to remain stable or improve from admission to
discharge, and were more likely to have an unfavorable
outcome. Additionally, stroke type was a strong predictor
of outcomes. Compared to those who experienced a SAH
stroke, those who had an ICH stroke were more likely to
have experienced a moderate to severe stroke based on both
admission and discharge NIHSS, were less likely to remain
stable or improve, and were more likely to experience an
unfavorable discharge destination.
Discussion
Compared to ischemic stroke, hemorrhagic stroke leads to
a higher mortality rate (22,23), increased need for palliative
care (24), and higher hospitalization costs (25) associated
with higher Medicare expenditures (26). This highlights the
need to predict outcomes and manage comorbidities before
hemorrhagic strokes occur. Studies have looked at the risk
of AD and dementia after stroke (27,28), but few studies
have looked at hemorrhagic stroke risk in patients with
AD (29). Our study found DM+/AD+ patients had more

Ann Transl Med 2021;9(17):1371 | https://dx.doi.org/10.21037/atm-21-1451
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severe hemorrhagic strokes (higher NIHSS) at admission
and discharge that contributed to a larger percentage with
unfavorable discharge destinations. No differences between
groups were observed for length of hospital stay and
inpatient outcomes.
The presence of comorbidities is known to increase
mortality following stroke (30,31). Specifically, high blood
glucose, as occurs in diabetes, is associated with early
mortality (32). An abnormal A1c may be an indicator that
the patient is prediabetic or not managing their diabetes
with their current regimen, possibly due to a lack of
diagnosis, ability to treat, or patient compliance.
DM increases the risk of developing AD (33-36), and
the metabolic changes associated with DM can initiate/
accelerate AD pathologies through oxidative stress,
inflammation, and vascular injury (37). AD is associated
with amyloid and tau pathologies that damage neurons or
weaken the vasculature. Changes in cognition associated
with AD may be associated with the weakening of the
cerebrovasculature that can present years before damage is
apparent. Higher percentage of prior strokes among the AD
population may be due to amyloid deposition (38), which
repeatedly weakens the vasculature. Diabetes treatment
has been shown to lower amyloid load (39,40). However,
the effects of controlling A1c values are controversial in
dementia (39-42) due to adverse effects of hypoglycemias
on the brain. DM+/AD+ subjects in KApSR have lower
A1c’s, indicating controlled diabetes, but significantly
worse NIHSS following hemorrhagic stroke. This suggests
the importance of controlling diabetes, while preventing
hypoglycemia, to prevent vascular injury and altered
cognition. Patients with AD have higher relative risk and
absolute rates of hemorrhagic stroke compared to non-AD
controls (10,29,43-45). In our analysis, when controlling for
age, the AD population had the worst outcomes.
Several limitations should be considered when
interpreting these results, including disparities in: diet
(46,47), physical activity (48), socio-economic status (49),
race (50), and drug use (51-54), all inherent to the rural
Appalachian population (55,56). We used the diagnosis of
AD rather than the broader umbrella term dementia. While
AD is just one type of dementia (57) it accounts for ~60–
70% of the cases (58). Diagnosis of AD and other dementias
may be severely underreported or underdiagnosed, as occurs
nationally (59-61), but may be heightened due to inherit
health disparities in rural Appalachia. Additional cognitive
and brain imaging diagnosis tools, such as computed
tomography (CT), magnetic resonance imaging (MRI), or

© Annals of Translational Medicine. All rights reserved.
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positron emission tomography (PET), were not available
in this study. Any current medications for comorbidities,
including diabetes, were also not available for our analysis.
Comorbidities can also affect ischemic stroke, which can
also lead to a secondary hemorrhagic stroke. As our analysis
only included hemorrhagic strokes coded as primary
diagnosis, the effect of diabetes and AD on a secondary
hemorrhagic stroke was not analyzed and may be considered
a limitation in our study. However, previous studies suggest
alternate comorbidities may be associated with secondary
hemorrhagic stroke following ischemic stroke. Arboix et al.
found hemorrhagic lacunar stroke patients were more like
to have hypertension, than diabetes (62) and patients with
hemorrhagic stroke following cardioembolic stroke had a
higher association with atrial fibrillation (63).
In conclusion, diabetes and AD should be considered
as risk factors for an unfavorable outcome following
hemorrhagic stroke. Diabetic screening and education
for the AD population/caregivers is critical in addressing
potential therapeutics to prevent hemorrhagic stroke.
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Supplementary
Table S1 Predictors of missing NIHSS
Predictor

Not missing NIHSS (n=1238)

Missing NIHSS (n=833)

Odds ratio (95% CI)

P value

DM+/AD+

11 (68.8%)

5 (31.2%)

Ref

0.613

DM+

369 (65.1%)

198 (34.9%)

0.96 (0.30–3.10)

AD+

23 (79.3%)

6 (20.7%)

0.49 (0.11–2.21)

DM-/AD-

835 (57.2%)

624 (42.8%)

0.96 (0.30–3.07)

65.63 (15.21)

50.04 (15.61)

0.99 (0.98–0.99)

AD+/DM+ group

Age, mean (SD)
Sex

<0.001
0.021

Male

646 (64.0%)

363 (36.0%)

Ref

Female

592 (55.7%)

470 (44.3%)

1.27 (1.04–1.54)

Race

0.056

White

1,112 (59.6%)

754 (40.4%)

Ref

Other

124 (61.7%)

77 (38.3%)

0.72 (0.52–1.01)

Stroke type

<0.001

ICH

1,033 (71.3%)

415 (28.7%)

Ref

SAH

205 (32.9%)

418 (67.1%)

4.38 (3.52–5.45)

1,128 (62.2%)

685 (37.8%)

0.67 (0.49–0.90)

0.008

Atrial fibrillation

241 (68.1%)

113 (31.9%)

1.04 (0.79–1.38)

0.760

Coronary artery disease

316 (65.4%)

167 (34.6%)

1.14 (0.88–1.49)

0.326

Tobacco

471 (58.8%)

330 (41.2%)

0.78 (0.63–0.96)

0.019

Obesity

192 (62.5%)

115 (37.5%)

0.82 (0.62–1.09)

0.167

Dyslipidemia

566 (69.2%)

252 (30.8%)

0.64 (0.52–0.80)

<0.001

Carotid stenosis

65 (82.3%)

14 (17.7%)

0.41 (0.22–0.76)

0.005

Prior stroke/transient ischemic attack

259 (70.0%)

111 (30.0%)

0.91 (0.69–1.18)

0.468

Acute myocardial infarction

74 (61.1%)

47 (38.8%)

0.86 (0.57–1.31)

0.483

History myocardial infarction

71 (59.2%)

49 (40.8%)

1.51 (0.98–2.33)

0.065

Comorbidities
Hypertension

Data are n (percent) and odds ratios with a 95% CI. Both P values and confidence intervals were calculated using Dunnett’s multiple
comparison procedure. AD, Alzheimer’s disease; CI, confidence interval; DM, diabetes mellitus; ICH, intracerebral hemorrhage; SD,
standard deviation; SAH, subarachnoid hemorrhage.
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